Nanotherapeutic Modulation of Human Neural Cells and Glioblastoma in Organoids and Monocultures by Zhang, Issan et al.
cells
Article
Nanotherapeutic Modulation of Human Neural Cells
and Glioblastoma in Organoids and Monocultures
Issan Zhang 1, Paula Lépine 2, Chanshuai Han 2, María Lacalle-Aurioles 2 , Carol X.-Q. Chen 2,
Rainer Haag 3 , Thomas M. Durcan 2 and Dusica Maysinger 1,*
1 Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir-William-Osler,
Montreal, QC H3G 1Y6, Canada; issan.zhang@mail.mcgill.ca
2 The Neuro’s Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street,
Montreal, QC H3A 2B4, Canada; paula.lepine@mcgill.ca (P.L.); chanshuai.han2@mcgill.ca (C.H.);
maria.lacalleaurioles@mcgill.ca (M.L.-A.); xiuqing.chen@mcgill.ca (C.X.-Q.C.);
thomas.durcan@mcgill.ca (T.M.D.)
3 Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustraße 3, 14195 Berlin, Germany;
haag@chemie.fu-berlin.de
* Correspondence: dusica.maysinger@mcgill.ca; Tel.: +1-514-398-1264
Received: 23 August 2020; Accepted: 5 November 2020; Published: 7 November 2020


Abstract: Inflammatory processes in the brain are orchestrated by microglia and astrocytes in
response to activators such as pathogen-associated molecular patterns, danger-associated molecular
patterns and some nanostructures. Microglia are the primary immune responders in the brain and
initiate responses amplified by astrocytes through intercellular signaling. Intercellular communication
between neural cells can be studied in cerebral organoids, co-cultures or in vivo. We used human
cerebral organoids and glioblastoma co-cultures to study glia modulation by dendritic polyglycerol
sulfate (dPGS). dPGS is an extensively studied nanostructure with inherent anti-inflammatory
properties. Under inflammatory conditions, lipocalin-2 levels in astrocytes are markedly increased
and indirectly enhanced by soluble factors released from hyperactive microglia. dPGS is an effective
anti-inflammatory modulator of these markers. Our results show that dPGS can enter neural cells
in cerebral organoids and glial cells in monocultures in a time-dependent manner. dPGS markedly
reduces lipocalin-2 abundance in the neural cells. Glioblastoma tumoroids of astrocytic origin respond
to activated microglia with enhanced invasiveness, whereas conditioned media from dPGS-treated
microglia reduce tumoroid invasiveness. Considering that many nanostructures have only been tested
in cancer cells and rodent models, experiments in human 3D cerebral organoids and co-cultures are
complementary in vitro models to evaluate nanotherapeutics in the pre-clinical setting. Thoroughly
characterized organoids and standardized procedures for their preparation are prerequisites to gain
information of translational value in nanomedicine. This study provides data for a well-characterized
dendrimer (dPGS) that modulates the activation state of human microglia implicated in brain
tumor invasiveness.
Keywords: cerebral organoids; nanomedicines; astrocytes; microglia; glioblastoma; lipocalin-2;
inflammation
1. Introduction
The brain is particularly challenging to model because of its complex structure and functions.
Neural cells constantly interact with each other through signaling molecules as well as cell–cell
contacts [1–3]. Monocultures are useful to answer cell type-specific questions, but processes involving
multiple cell types benefit from the use of co-cultures and organoid models [4–6].
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Although primary dissociated and organotypic slice cultures are attractive models to investigate
molecular mechanisms and functions, particularly for genetic knock-ins and knock-outs, key differences
between human and mouse brains can impact the translational potential of experimental results [7,8].
Primary human neural cells are valuable resources, but their use is often restrained by access or
methodological limitations. Advances in stem cell research have led to the development of organoids
as in vitro models resembling human tissues in structure and complexity [4–6]. Cerebral organoids
differentiated from induced pluripotent stem cells (iPSCs) show organized neurons and astrocytes in
three-dimensions (3D) [9,10].
Nanostructures have been extensively studied in different cell lines and rodents [11], but a limited
amount of data are available in human primary cells and organoids. Rodent models were valuable for
the assessment of absorption, distribution, elimination and metabolism of nanomedicines. They clearly
showed problems related to the entry of some nanostructures into the cerebral parenchyma due to the
blood–brain barrier [12,13]. Studies in rodents also provided information on how nanostructures can
be tuned in terms of size, shape and surface properties to facilitate brain entry. Similar studies are
clearly not possible in humans and are rare in non-human primate models (e.g., Onpattro, Abraxane,
BIND-014) [14–16]. Organoids therefore offer a valuable platform for the testing of organic and
metallic nanostructures.
Among the nanostructures that have been studied in rodents, which showed pronounced intrinsic
anti-inflammatory properties, is dendritic polyglycerol sulfate (dPGS) [17–21]. Their structures with
terminal sulfate groups resemble that of heparan sulfate, which exerts anti-coagulant effects [17,22–24].
In contrast to heparan sulfate, dPGS shows primarily anti-inflammatory activity with relatively weak
anti-coagulant effects that are size- and charge-dependent. Earlier studies indicated that dPGS can
effectively reduce hyperactivity of microglia stimulated by danger-associated molecular patterns and
lipopolysaccharide (LPS) in mice [18,19,25]. Microglia are the resident immune cells of the central
nervous system and constantly survey their surroundings under physiological conditions [26–28].
Their morphology is altered and their phagocytic functions are elevated under many pathological
conditions, making them attractive targets for nanotherapeutic interventions. Our previous studies
showed that dPGS can modulate microglial activation in response to pathogen-associated molecular
patterns and misfolded proteins (e.g., amyloid beta), thereby reducing losses in dendritic spine density
of excitatory hippocampal neurons in mouse organotypic slice cultures [18,19,25]. These studies also
showed that hyperactive microglia generate reactive astrocytes through the release of acute-phase
cytokines such as interleukin-6, tumor necrosis factor alpha and lipocalin-2 (LCN2). However,
the abundance and release of LCN2 in human neural cells has not yet been reported. We tested if dPGS
can modulate LCN2 in a human cerebral organoid model.
Aside from establishing human cerebral organoids, we also used glioblastoma tumoroids to
investigate the effectiveness of nanotherapeutics in the brain tumor microenvironment. Glioblastomas
are mainly astrocytomas characterized by their infiltrative nature [29]. Microglia and normal astrocytes
in the glioblastoma environment promote disease progression by secreting soluble factors (e.g., cytokines
and growth factors) [30–32]. By combining reconstituted 3D models of glioblastoma (tumoroids) with
organoids and modulating the activity of microglia with dPGS, we demonstrate that dPGS could be a
powerful therapeutic agent that can reduce inflammatory markers and glioblastoma invasiveness.
2. Materials and Methods
2.1. Generation of Cerebral Organoids from Human iPSC
Procedures for culturing human iPSCs, embedding organoids in optimal cutting temperature
(OCT) blocks, cryosectioning and immunostaining were all described previously [10]. The cell-line
used was the NCRM1 iPSC line obtained from the National Institutes of Health. The method used
to generate the 3D cerebral organoids was adapted from the protocol published by Lancaster and
Knoblich [9]. Compositions of the different media are the same and reagents used are similar,
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except for: DMEM-F12 (Gibco, Ottawa, ON, Canada), human embryonic stem cell (hESC) quality
fetal bovine serum (FBS) (Wisent, St-Bruno, QC, Canada), MEM Non-Essential Amino Acids Solution
(MEM-NEAA) (Multicell, Montreal, QC, Canada), 2-mercaptoethanol (Millipore Sigma, Oakville,
ON, Canada), Y27632 Rho-associated protein kinase (ROCK) inhibitor (Selleckchem, Burlington, ON,
Canada), N2 supplement (Gibco) and Penicillin-Streptomycin (Multicell).
For the generation and maintenance of embryoid bodies (EBs, days 0–11), we started from a
100 mm dish with iPSCs at 70% confluence with high quality (less than 10% differentiated cells).
Cells were washed with DMEM-F12 and dissociated with Accutase to generate a suspension of single
cells. Cells were gently resuspended in hESC media containing ROCK inhibitor [9], basic fibroblast
growth factor (FGF-b) and plated at a density of 10,000 cells/well in a 96-well ultra-low attachment
U-bottomed plate (Corning, Burlington, ON, Canada). Plates were centrifuged at 1200 rpm for 10 min
and incubated at 37 ◦C, 5% CO2 for 48 h. During day 2, a half media change was made, followed
by a media change every other day up to day 11. Images of EBs were recorded with Evos XL Core
Microscope (Thermo Fisher Scientific, Ottawa, ON, Canada) every 2 days during media changes to
measure their diameter using the Image J software (U. S. National Institutes of Health, Bethesda,
Maryland, USA). Once EBs had reached ≥ 350 µm in diameter, hESC media was switched to be without
ROCK inhibitor and FGF-b [9]. When EBs were about 500–600 µm in diameter with smooth and bright
edges, the media was switched to neuronal induction media (NIM). EBs were maintained in NIM for
4–5 days until the outer surface was optically translucent and ready to be embedded in Matrigel®
(Corning) containing reduced growth factor droplets.
Matrigel® was thawed on ice. After media removal from each well containing the EBs, 30 µL of
Matrigel® was added per well and incubated for 30 min at 37 ◦C. Next, 200 µL of final differentiation
media without vitamin A [9] was added per well. Using a 1000 µL cut tip, the Matrigel®-embedded
organoids were transferred into an uncoated 6-well ultra-low attachment plate (Corning) with 4 mL of
final differentiation media without vitamin A per well. A maximum of five organoids were added and
maintained per well to avoid fusion. Following transfer, plates were left for 48 h in stationary culture.
After 48 h, media was changed to fresh final differentiation media without vitamin A, followed by a
second 48 h incubation. Following the second media change, plates were transferred onto an orbital
shaker set at 70 rpm (Scientific Industries Inc., Bohemia, NY, USA) housed in a 37 ◦C incubator.
Media was changed every 3 days with fresh final differentiation media with vitamin A until the
organoids were ready for analysis.
2.2. Immunofluorescence (IF) Staining in Organoids
Cerebral organoids were fixed with 4% paraformaldehyde (overnight at 4 ◦C), washed in
phosphate-buffered saline (PBS, Multicell), dehydrated in 20% sucrose (1–3 days) and embedded
in OCT Compound (Thermo Fisher Scientific). Blocks were kept at −80 ◦C until needed. For IF,
samples were sectioned (20 µm) in a cryostat (Cryostar NX70, Thermo Fisher Scientific), air dried at
room temperature (RT) and kept at −20 ◦C before IF staining. Cryosections were rehydrated in PBS
(15 min) and permeabilized/blocked in blocking solution (1 h at room temperature, RT) containing:
0.2% Triton X-100 (Millipore Sigma), 0.05% bovine serum albumin and 5% normal donkey serum
in PBS, before incubation (overnight at 4 ◦C) with primary antibodies. Antibodies used were as
follows: mouse anti-Nestin (1:250, Developmental Studies Hybridoma Bank, Iowa City, IA, USA,
rat-401), rabbit anti-SOX2 (1:500, Millipore, Oakville, ON, Canada, AB5603), chicken anti-MAP2 (1:1000,
EnCor Biotechnology, Gainesville, FL, USA, CPCA-MAP2), rat anti-CTIP2 (1:500, Abcam, Toronto,
ON, Canada, ab18465), rabbit anti-GFAP (1:250 Millipore, MAB144P), chicken anti-Beta III Tubulin
(1:400, Millipore, AB9354), rabbit anti-Nestin (1:200, Abcam, ab92391) and rat anti-lipocalin-2 (1:500,
R&D Systems, Toronto, ON, Canada, MAB1757). Sections were then washed in PBS (45 min) and
incubated (1 h at RT) with secondary antibodies in blocking solution: goat anti-rat Dylight 488 (1:300,
Abcam, ab96887), donkey anti-rabbit Dylight 594 (1:400, Abcam, ab96877), donkey anti-chicken Alexa
647 (1:500, Invitrogen, Ottawa, ON, Canada, A21447), donkey anti-mouse Dylight 550 (1:200, Abcam,
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ab96876), goat anti-chicken Dylight 650 (1:200, Abcam, ab96950), donkey anti-rabbit Dylight 550
(1:200, Abcam, ab96892) and goat anti-rat Alexa Fluor 647 (1:500, Thermo Fisher Scientific, A21247).
Sections were washed (45 min) with PBS and incubated (10 min at RT) with Hoechst 33342 (1:5000,
Thermo Fischer Scientific) in PBS, washed in PBS (10 min) and mounted using Aqua-Poly/Mount
(Polysciences Inc., Warrington, PA, USA). Samples were imaged on a Leica TCS SP8 confocal microscope
(Leica, Richmond Hill, ON, Canada) at a 20×magnification.
2.3. Cell Culture
U251N human glioblastoma cells and HMC3 human microglia were originally obtained from the
American Type Culture Collection. Unless otherwise indicated, cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM, Thermo Fisher Scientific) supplemented with 5% fetal bovine serum
(FBS, Wisent) and 1% Penicillin-Streptomycin (Thermo Fisher Scientific). Primary human astrocytes
were obtained from Dr. Jack Antel’s lab and maintained in DMEM supplemented with 5% FBS and 1%
Penicillin-Streptomycin. Primary astrocytes were kept at passages below five. Conditioned media was
obtained from cell cultures maintained in the exponential growth phase and used fresh at 50% (v/v)
in fresh media following centrifugation (3,000 rpm, 5 min) to remove cell debris. When used for the
treatment of cerebral organoids, conditioned media was prepared using organoid media.
2.4. Time-Dependent dPG/dPGS Internalization in Organoids and Tumoroids
Human cerebral organoids were treated with dPG-Cy5 (1 µM) or dPGS-Cy5 (1 µM) for 1 h, 4 h
or 24 h, then used for IF staining or direct imaging. For direct imaging, organoids were fixed in
4% paraformaldehyde overnight and nuclei were labeled with Hoechst 33342 (10 µM, overnight).
Organoids were washed in PBS and imaged using a fluorescence microscope. Fluorescence was
analyzed in ImageJ. Glioblastoma tumoroids were treated with dPG-Cy5 (1 µM) or dPGS-Cy5 (1 µM)
for 24 h, then washed twice with PBS before imaging using a fluorescence microscope.
2.5. Western Blot
Western blot analysis followed published procedures [33]. In brief, organoids were washed twice
in cold PBS, then were cut into small pieces using a razor blade and incubated in RIPA lysis buffer
for 30 min on ice. Monolayer cells were washed twice with cold PBS, then incubated in RIPA lysis
buffer for 30 min on ice. Lysates were vortexed for 10 sec every 10 min and lastly centrifuged for
30 min at 4 ◦C and 13,000 rpm. Lysates and media samples were separated by SDS-PAGE and blotted
onto PVDF membranes (Bio-Rad, Mississauga, ON, Canada). Blocked membranes were probed with
primary antibodies: rat anti-lipocalin-2 (1:500, R&D Systems, MAB1757), rabbit anti-NFκB p65 (1:1000,
Abcam, ab16502), mouse anti-STAT3 (1:1000, Abcam, ab119352), mouse anti-β-actin (1:5000, Millipore
Sigma, A5316) or mouse anti-alpha-tubulin (1:5000, Abcam, ab7291) overnight at 4 ◦C. Membranes
were washed and incubated with secondary antibodies (goat anti-rat HRP, 1:1000, Thermo Fisher
Scientific, 31470, goat anti-rabbit HRP, 1:1000, Bio-Rad, 1706515 and horse anti-mouse HRP, 1:5000,
Cell Signaling, Burlington, ON, Canada, 7076S) for 1 h at RT. Membranes were washed and incubated
with enhanced chemiluminescence substrate (Bio-Rad) for 5 min, signals were acquired with an
Amersham 6000 imager (Amersham, Oakville, ON, Canada) or on film, and quantified in ImageJ.
2.6. Collagen Invasion Assay
U251N tumoroids and human astrocyte spheroids were prepared using the hanging drop
method [34]. Briefly, drops of 5,000 cells in 30 µL medium were pipetted onto the inner side of a
100 mm Petri dish (Thermo Fisher Scientific) lid. The lid was quickly flipped to cover the Petri dish
filled with 20 mL PBS. Hanging drops were cultured at 37 ◦C for 48 h to allow tumoroids and spheroids
to form. Tumoroids and spheroids were then gently scooped into a medium-filled Petri dish coated
with 2% agarose (dissolved in PBS) and cultured for 48 h. Tumoroids and spheroids were implanted in
collagen gel (Advanced BioMatrix, San Diego, CA, USA), in the presence or absence of primary human
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astrocytes (7,000 cells) and human HMC3 microglia (3,000 cells) dispersed in 200 µL gel. Gels were
covered with 200 µL DMEM with or without treatment. Tumoroids and spheroids were imaged using
light microscopy immediately after implantation (time = 0 day) and after 6 days. The average distance
of cell outgrowth into the surrounding collagen was measured in ImageJ. For invasion assays of
tumoroids into organoids, fluorescently-labeled tumoroids were prepared using U251N cells incubated
with CellTracker Red (Thermo Fisher Scientific) following recommendations from the manufacturer.
Tumoroids were placed in culture with organoids and observed to adhere after 24 h. Cultures were
imaged using a fluorescence microscope over 6 days.
2.7. Immunocytochemistry
Cells were seeded at 5,000 cells/coverslip on glass coverslips (Merlan Scientific, Mississauga,
ON, Canada) coated with poly-D-lysine (Millipore Sigma). Cells were cultured for 24 h (U251N and
HMC3) or 48 h (primary human astrocytes) before treatment. Following treatment, cells were fixed
in 4% paraformaldehyde (10 min), permeabilized with 0.1% Triton X-100 (10 min), blocked in 10%
goat serum in PBS (Gibco) for 1 h and incubated with primary antibodies overnight at 4 ◦C: rabbit
anti-GFAP (1:500, Abcam, ab7260), mouse anti-Lamp1 (1:500, Developmental Studies Hybridoma Bank,
H4A3-c), rat anti-lipocalin-2 (1:500, R&D Systems, MAB1757), rabbit anti-NFkB p65 (1:500, Abcam,
ab16502) or rabbit anti-phospho-STAT3 Y705 (1:500, Abcam, ab76315). Cells were washed in PBS three
times and incubated with secondary antibodies for 1 h at RT: goat anti-rabbit Alexa Fluor 488 (1:1000,
Thermo Fisher, Mississauga, ON, Canada, A27034), goat anti-rat Alexa Fluor 647 (1:500, Thermo Fisher,
A21247) or goat anti-mouse Alexa Fluor 488 (1:1000, Thermo Fisher, A28175). Cells were washed
with PBS and nuclei were labeled with Hoechst 33342 (10 µM, 10 min). After three more washings
with PBS, coverslips were mounted on microscope slides (Diamed, Mississauga, ON, Canada) using
Aqua-Poly/Mount. Samples were imaged using a fluorescence microscope (Leica DMI4000B, Leica)
and intracellular fluorescence was analyzed in ImageJ. The nuclear and/or cytoplasmic fluorescence
of NFκB, LCN2 and phosphor-STAT3 for each cell was measured and normalized to the nuclear or
cytoplasmic area. The background fluorescence was subtracted.
2.8. Immunohistochemistry
Immunohistochemistry was performed as previously published [33]. In brief, human brain
sections were dewaxed in xylene and rehydrated in ethanol. Antigen retrieval was performed in citrate
buffer. Following blocking, samples were incubated with primary antibodies: rat anti-lipocalin-2
(1:500, R&D Systems, MAB1757), mouse anti-IBA1 (1:300, Invitrogen, MA5-27726) or rabbit anti-GFAP
(1:250 Millipore, MAB144P) overnight at 4 ◦C. Samples were washed and incubated with secondary
antibodies: goat anti-rat Alexa Fluor 647 (1:500, Thermo Fisher Scientific, A21247), goat anti-mouse
Alexa Fluor 647 (1:300, Thermo Fisher Scientific, A28181) or goat anti-rabbit Alexa Fluor 488 (1:500,
Thermo Fisher, A27034) for 1 h at RT. Nuclei were labeled with DAPI (1µg/mL, 5 min, Molecular Probes,
Ottawa, ON, Canada) and samples were mounted on microscope slides using Dako mounting medium
(Dako, Burlington, ON, Canada). Samples were imaged using a fluorescence microscope. The samples
were harvested under a protocol approved by the Montreal Neurological Hospital’s research ethics
board (NEU-10-066). Consent was given by all patients and controls (aged 55–76). Tissues were from
the cerebral cortex.
2.9. Lipid Droplet Imaging
Cells seeded on glass coverslips at 5,000 cells/coverslip were cultured for 24 h before treatment.
Following treatment, cells were washed twice with PBS and fixed in 4% paraformaldehyde (10 min).
Cells were washed with PBS and incubated with BODIPY 493/503 (10 µM, Thermo Fisher) and
Hoechst 33342 (10 µM) for 10 min. Cells were washed with PBS four times, then mounted on
microscope slides using EverBrite (Biotium, Burlington, ON, Canada). Samples were imaged using a
fluorescence microscope.
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2.10. MTT Assay
Following treatment, organoids were washed in PBS twice and incubated in fresh media in
the presence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (0.5 mg/mL,
Millipore Sigma) for 1 h at 37 ◦C. The media was removed, and cells were lysed in 500 µL dimethyl
sulfoxide (Santa Cruz, Dallas, TX, USA). Samples were measured at 595 nm in triplicate using a
microplate reader (Spark 10M, Tecan, Männedorf, Switzerland). Measurements were normalized to
the organoid weight.
2.11. Statistics
Statistical significance was determined using one-way ANOVA followed by the Student’s
t-test. p-values lesser than 0.05 were deemed significant. The Bonferroni correction was applied
for multiple comparisons.
3. Results
3.1. dPGS Are Internalized in 3D Cerebral Organoids
Human cerebral organoids were generated from human iPSCs according to an established
protocol [9]. A timeline of organoid formation and biomarkers used to delineate dynamic linage
progression is illustrated in Figure S1. We used these organoids after a 100-day maturation to test
dendritic polyglycerol sulfate (dPGS) as a model nanostructure with anti-inflammatory properties in
human neural cells, as well as other types of emerging nanostructures with biomedical applications,
such as metallic gold nanoclusters [35–39]. Gold nanoclusters have been shown to affect cellular stress
and organellar function thanks to their unique physicochemical properties, but little work has been
done in human neural cells. The nanostructures were screened for cytotoxic effects (Figure 1a and
Figure S2) and results showed that they can be studied in human neural cells without jeopardizing the
viability of the organoid cultures. This provides the basis for further investigations on nanomedical
applications in a translationally-relevant model. The first step was to show if dPGS was internalized
by neural cells within the organoids themselves. To this end, we treated organoids with fluorescently
(Cy5)-labeled dPGS (Figure 1). Time-course experiments showed that dPGS-Cy5 was internalized
within 1 h (12.8 ± 2.2 SEM fold increase over baseline fluorescence), then progressively more over 24 h
(64.5 ± 11.4 SEM fold increase) (Figure 1b,c). Compared to dPGS, internalization of the non-sulfated
dendritic polyglycerol (dPG) was low (8.7 ± 2.1 SEM fold increase after 24 h) (Figure 1b,c), underlining
the important role of the terminal sulfate groups for cell internalization. In the current study, we showed
that GFAP-labeled astrocytes within the outermost layer (200–300 µm) of the cerebral organoids contain
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Figure 1. (a) Schematic representation of cerebral organoid usage for nanostructure screening.
(b) Human cerebral organoids were treated with dendritic polyglycerol (dPG)-Cy5 (1 µM) or dendritic
polyglycerol sulfate (dPGS)-Cy5 (1 µM) for 1 h, 4 h or 24 h. Nuclei were labeled with Hoechst 33342.
Organoids were imaged using a fluorescence microscope. (c) Cy5 fluorescence in organoids was
analyzed in ImageJ. Shown are the average fluorescence per condition ± SEM. At least 90 organoids
were analyzed from three independent experiments. *** p < 0.001 (d) Fluorescence micrographs of
human cerebral organoids treated with dPG-Cy5 (1 µM) or dPGS-Cy5 (1 µM) for 24 h and labeled for
glial fibrillary acidic protein (GFAP). Nuclei were labeled with Hoechst 33342. (e) Primary human
astrocytes and human HMC3 microglia internalization of dPGS-Cy5 (1 µM) after 24 h. dPGS-Cy5 (red)
is partially co-localized with Lamp1-labeled lysosomal compartments (green). The negative control was
prepared in the absence of dPGS-Cy5 and primary antibody to account for background fluorescence.
Nuclei were labeled with Hoechst 33342 (blue). Cells were imaged using a fluorescence microscope.
(f) Shown are the average intracellular Cy5 fluorescence per cell expressed as fold change from untreated
cells ± SD. At least 90 cells were analyzed in two independent experiments. n.s. Non-significant.
3.2. dPGS Internalization in Human Microglia and Normal Astrocytes
Given the importance of glial cells in regulating inflammatory processes in the brain, we further
studied the intracellular effects of dPGS in astrocytes and particularly microglia, which are absent from
the cerebral organoids. We established in cell monolayer cultures that human microglia and astrocytes
internalized comparable amounts of dPGS within 24 h of treatment (Figure 1e,f). Fluorescence imaging
at the single cell level showed that dPGS-Cy5 accumulated in the perinuclear area (Figure 1e), and was
partially co-localized with lysosomal compartments labeled with Lamp1 [40]. Given that microglia
activated by pro-inflammagens (e.g., LPS) are associated with increased sequestration of neutral lipids
into lipid droplets (LDs) [41,42] (Figure S3b), we investigated if dPGS could have modulatory effects
on lysosomes, which interact with LDs through lipophagy and other processes [43,44]. This was
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suggested by changes in lysosomal positioning, with an increase in perinuclear lysosomes (Figure S3a).
In turn, treatment with dPGS prevented LPS-induced lipid droplet accumulation (Figure S3b).
3.3. dPGS Reduced Microglia-Stimulated Lipocalin-2 in Cerebral Organoid Models
Considering the importance of microglia-astrocyte crosstalk in rodent [19] and human neural
cells [1,3], we measured LCN2 abundance in human neural cells in response to LPS, a prototypical
pro-inflammagen whose levels are exacerbated in endotoxemia and sepsis. The presence of microglia
is required to stimulate the synthesis of LCN2 in the neural cells, as levels in response to LPS remained
comparable to that of the untreated control in the absence of microglia from the organoids (Figure 2a,b
and Figure S4). In turn, conditioned media from LPS-stimulated microglia induced a significant increase
in intracellular and extracellular LCN2 in the cerebral organoid cultures (Figure 2c–e), confirming
that this upregulation is microglia-dependent in human neural cells. Given that astrocytes play
a significant role in inflammatory processes in the brain, we investigated if there was increased
LCN2 abundance in these cells in response to microglia activation. Similarly to the results from
cerebral organoids, direct stimulation of astrocytes with LPS did not have a significant effect (Figure 2f).
In contrast, treatment with conditioned media from LPS-activated microglia increased LCN2 abundance,
whereas the presence of dPGS returned LCN2 abundance to control levels (Figure 2f). dPGS alone and
conditioned media from resting microglia did not have significant effects (Figure 2d–f). Finally, to show
that dPGS is not cytotoxic to human neural cells, we measured mitochondrial metabolic activity using
the MTT assay. Results from these studies showed that neither dPGS nor dPG affected mitochondrial
metabolic activity in 3D organoids for up to 72 h (Figure S2). Our earlier studies indicated that
in rodent cells, concentrations of dPGS up to 100 µM did not cause any notable cytotoxicity [18].
These results encouraged us to investigate dPGS as a microglia modulator and indirect suppressor of
glioblastoma invasiveness.Cells 2020, 9, x FOR PEER REVIEW 9 of 18 
 
Figure 2. Lipocalin-2 levels in human cerebral organoids. (a) Micrographs of lipocalin-2 (LCN2) 
detected by immunofluorescence in organoid cryosections following treatment with LPS (10 ng/mL) 
for 24 h. Astrocytes were labeled with GFAP and nuclei with Hoechst 33342. The negative control was 
prepared in the absence of primary antibodies to account for background fluorescence. Samples were 
imaged using a fluorescence microscope. (b) LCN2 levels in organoids treated with 
lipopolysaccharide (LPS) (10 ng/mL) with or without dPG (1 μM) and dPGS (1 μM) for 24 h and 
Figure 2. Cont.
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Figure 2. Lipocalin-2 levels in human cerebral organoids. (a) Micrographs of lipocalin-2 (LCN2)
detected by immunofluorescence in organoid cryosections following treatment with LPS (10 ng/mL) for
24 h. Astrocytes were labeled with GFAP and nuclei with Hoechst 33342. The negative control was
prepared in the absence of primary antibodies to account for background fluorescence. Samples were
imaged using a fluorescence microscope. (b) LCN2 levels in organoids treated with lipopolysaccharide
(LPS) (10 ng/mL) with or without dPG (1 µM) and dPGS (1 µM) for 24 h and measured by Western
blot, with beta-actin as loading control. Quantification shown are the average intracellular LCN2 levels
±SD in organoids based on immunofluorescence images shown in (a). A total of 27 samples were
analyzed from three independent experiments. (c) Schematic representation of media conditioning
from microglia used for cerebral organoid treatment. (d) Representative fluorescence micrographs
of intracellular LCN2 levels in organoids treated with conditioned media from microglia (MCM)
treated with LPS (10 ng/mL), dPGS (1 µM) for 24 h. Quantifications show the average and single-cell
levels of LCN2 fluorescence in cryosections. A total of 1017 cells were analyzed from independent
experiments. *** p < 0.001 (e) LCN2 levels from organoids treated as in (d) and measured by Western
blot, with alpha-tubulin as loading control. Shown are the average LCN2 levels from two independent
experiments. * p < 0.05 (f) Fluorescence micrographs of LCN2 abundance in primary human astrocytes
treated as in (d) and measured using immunocytochemistry. Shown are the average intracellular LCN2
levels in astrocytes as fold increase of the untreated control. A total of 477 cells from two independent
experiments were analyzed. *** p < 0.001.
3.4. Microglia and dPGS Modulate Glioblastoma Invasiveness
Glioblastoma multiforme is an aggressive brain tumor of astrocytic origin for which complete
resection is often impossible due to its invasive nature [29,45]. To model the impact of microglia and
astrocytes on glioblastoma invasiveness, we designed a 3D invasion assay examining the propensity
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of the cancer cells to migrate into the surrounding collagen matrix. Human microglia and primary
human astrocytes were embedded into the collagen matrix, wherein a tumoroid was then implanted
(Figure 3a). Over time, the normal neural cells extend processes while cancer cells migrate radially
from the tumoroid. Glioblastoma outgrowth from the tumoroid into the surrounding collagen
was facilitated by the presence of microglia and astrocytes (Figure 3a,b), an effect replicated using
microglia-conditioned media and inhibited by dPGS (Figure 3c,d). This indicates that neural cells
secrete factors (extracellular matrix degradation enzymes, cytokines, growth factors) that can stimulate
tumor invasiveness [46–48]. In contrast, tumoroids grown in isolation or within cerebral organoids
in the absence of microglia had comparatively less outgrowth over time (Figure 3a,b and Figure S5),
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 Figure 3. Glioblastoma (GBM) invasiveness in 3D co-cultures. (a) Collagen gels were seeded with
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3D co-cultures after 6 days. Shown are the average distance of outgrowth from the tumoroid as a
fold change of the tumoroid monoculture ±SEM. A total of 32 tumoroids were tested from at least
three independent experiments. * p < 0.05 (c) Schematic representation of microglial conditioned
media (MCM) used to treat collagen-embedded tumoroids. (d) Glioblastoma tumoroid outgrowth
in the presence of conditioned media from microglia treated or not with dPGS (1 µM) after 6 days
±SEM. A total of 29 tumoroids were tested from at least four independent experiments. * p < 0.05
(e) Representative fluorescence micrographs showing intracellular LCN2 (red) in glioblastoma cells in
the presence or absence of microglia cells in direct co-culture and dPGS (1 µM) for 24 h. LCN2 was
fluorescently immunolabeled and cells were imaged using a fluorescence microscope. Quantifications
show the average intracellular LCN2 levels ± SD per cell. At least 500 cells were analyzed from five
independent experiments. *** p < 0.001; n.s. Non-significant. (f) Fluorescence micrographs of LCN2
(red) and GFAP (white) in human brain sections from non-cancerous brain or glioblastoma tumor
tissues. LCN2 and GFAP were fluorescently labeled by immunohistochemistry and imaged using a
fluorescence microscope. (g,h) Activation of transcription factors NFκB and STAT3 in microglia in
response to glioblastoma secreted factors. Human HMC3 microglia were treated with glioblastoma
conditioned media (GCM) for 24 h, after which NFκB p65 and phosphorylated STAT3 Tyr705 were
fluorescently immunolabeled (red) and cells were imaged using a fluorescence microscope. Shown are
(g) the average nuclear NFκB p65 level per cell ± SEM (237 cells from three independent experiments)
and (h) the average pSTAT3 Y705 level per cell ± SEM (317 cells from three independent experiments)
*** p < 0.001. (i) Total NFκB p65 and STAT3 protein abundance in microglia treated as in (g,h). Protein
levels were determined by measurements of immunopositive bands in Western blots. Alpha-tubulin
was used as loading control. Shown are the average protein abundance of NFκB p65 and STAT3 from
three independent experiments. n.s. Non-significant.
To characterize the effects of glioblastoma on its surrounding immune cells, glioblastoma cells
were directly co-cultured with microglia cells and showed significantly higher LCN2 levels compared
to glioblastoma cells in monoculture (Figure 3e). High LCN2 and GFAP levels were also observed in
tumor tissues from glioblastoma patients as compared to control brain tissues (Figure 3f). To investigate
the mechanism behind LCN2 upregulation, microglia were stimulated with glioblastoma-conditioned
media. This resulted in increased nuclear NFκB and STAT3 phosphorylation, two key transcription
factors for immune activation (Figure 3g,h) that are also hyperactivated in glioblastoma. The protein
levels of total NFκB and STAT3 in the cells remained comparable to the control (Figure 3i).
On the other hand, dPGS was internalized into glioblastoma tumoroids (Figure S7) and decreased
LCN2 levels in glioblastoma cells in vitro (Figure 3e). This demonstrates proof of concept for using
dPGS as a modulator of the tumor microenvironment (Figure 4).
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and glioblastoma crosstalk. (a) dPGS is internalized in cerebral organoids, and (b) downregulates
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(e.g., lipid droplets) and (d) glioblastoma invasiveness.
4. Discussion
The key question addressed in this study is: can dendritic polyglycerol sulfates with intrinsic
anti-inflammatory properties reduce inflammatory markers in cerebral organoids and glioblastoma
invasiveness by modulating microglia activity? Mechanistic studies in 3D human neural cultures with
new drugs or nanostructures are sparse due to the limited availability of neural tissues. To overcome
such a problem, several protocols have been developed for the generation of 3D cerebral organoids and
other types of organoids [4,5,7,9]. Human cerebral organoids derived from iPSCs showing properties
of different neural cell types are valuable models to study the interactions and effects of nanostructures
in 3D. One of the most advanced organoids containing vasculature resembling that of the brain was
recently proposed to investigate physiology and pathological changes in neurological disorders [49].
Although our organoids are not as complex as Cakir’s, we took advantage of cerebral organoids to
reveal how microglia exposed to the pro-inflammagen LPS and the dendritic nanostructure dPGS affect
astrocyte reactivity. We show clear anti-inflammatory effects from dPGS and provide the first evidence
for this in human brain cells. There are still several limitations to overcome: (1) the integration of
resident and peripheral immune cells recruited chemotactically and (2) the contribution of endothelial
cells in vasculature as part of the blood–brain barrier.
Our results in organoid cultures showed that the presence of sulfate groups on dPGS was critical for
the internalization of nanostructures, as it allowed binding to selectin receptors [17,19,22]. Intracellular
changes associated with dPGS included an increase in perinuclear lysosomes, which typically have
lower luminal pH and increased degradation activity [44,50], functions often impaired in aging and
neurodegenerative diseases. This is interesting given the role of lysosomes in processing LDs, which are
upregulated in inflammation and cancer [41,42]. LDs are promiscuous organelles: depending on the cell
type, cellular context and their intracellular location, they can play a protective role or become damaging
to neural and other cells if peroxidized lipids are released. In aggressive tumors (e.g., glioblastoma
and breast), they provide energy for cancer cells to thrive and can sequester lipophilic anticancer
Cells 2020, 9, 2434 13 of 17
agents, reducing the rate at which they reach their desirable targets [51–53]. Their numbers are highly
upregulated in glioblastoma compared to normal astrocytes (Figure S3c,d), and their inhibition was
shown to enhance the effectiveness of pharmacological agents [51].
As now shown in human neural cells, LCN2 can be produced by microglia-stimulated astrocytes.
Microglia themselves are not significant contributors to LCN2 upregulation due to the LCN2 gene
being suppressed by SRSF3 [54]. Instead, they secrete other cytokines (e.g., IL-6, TNFα) and alarmins
under pro-inflammatory conditions that can activate astrocytes and other neural cells [54,55]. Several of
these were shown to bind heparan sulfate [23,56], suggesting that dPGS prevented microglia-mediated
LCN2 production by blocking some soluble factors and preventing downstream signaling (Figure 2d,e).
One of the candidate cytokines is interleukin-6 released from microglia, to which dPGS was shown to
bind in our earlier studies using surface plasmon resonance [19].
Cytokines and alarmins play key roles in the tumor microenvironment [57–61]. The cancer cells
secrete factors that actively recruit microglia and peripheral macrophages to the tumor site. In turn,
these immune cells produce cytokine and growth factors that can promote cancer progression [32]. In this
context, microglia-astrocyte crosstalk forms a positive feedback loop that maintains an unfavorable
tumor microenvironment [30,62]. LCN2 is an acute-phase protein with emerging roles in the brain and
in cancer. It was shown to complex with and enhance the activity of metalloproteinase-9, a protease
secreted by cancer cells that breaks down the extracellular matrix and promotes invasiveness [63,64].
This is significant given that dPGS can downregulate LCN2 in neural cells and decrease glioblastoma
invasiveness. dPGS can bind P-selectin, which is expressed in the tumor endothelium and in
glioblastoma cells [65]. As dPGS can also serve as a nanocarrier, it has the potential to deliver
anti-cancer agents [65,66]. Nanocarriers such as functionalized dendrimers for siRNA and drug
delivery [67–69] merit testing in human organoid models to reveal how combination therapy could
affect interplay between cancer cells and the tumor microenvironment. The modulatory effect of
dPGS on organelles could impact glioblastoma cells in several ways: (1) the increase in perinuclear
lysosomes could decrease lysosomal exocytosis and the release of extracellular matrix-degrading
enzymes (e.g., cathepsins) [70,71], (2) a reduction in lipid droplet size and number [72] is an indicator of
reduced microglia hyperactivity, thus fewer cytokines and trophic factors contributing to glioblastoma
invasiveness and (3) a decrease in lipid droplets prevents the sequestration of lipophilic anti-cancer
agents, allowing them to reach their intracellular targets (e.g., curcumin) [51].
5. Conclusions
Our results show that dPGS is an attractive candidate as an anti-inflammatory polyglycerol
dendrimer able to modulate human microglia-astrocyte crosstalk. This dendrimer regulated lipocalin
2 abundance in human neural organoids. In the context of inflammation associated with glioblastoma
multiforme, dPGS limited glioblastoma invasiveness by modulating microglial activation. Overall,
these studies propose the evaluation of well-defined nanostructures in well-characterized human
organoids and co-cultures. Cerebral organoids merit further studies as complementary 3D models in
nanoscience, but they require rigorous characterization and application of standardized procedures to
be widely used [73]. Such three-dimensional systems together with co-cultures and in vivo experiments
will provide a valuable evaluation platform for the internalization, cytotoxicity and modulatory effects
of nanotherapeutics in human neural cells.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/11/2434/s1,
Figure S1: Maturation and characterization of cerebral organoids, Figure S2: Mitochondrial metabolic activity in
cerebral organoids following treatment with nanostructures, Figure S3: Changes in lysosomes and lipid droplets in
activated microglia, Figure S4: Absence of microglia in the cerebral organoids, Figure S5: Glioblastoma tumoroid
invasiveness in cerebral organoids, Figure S6: Movement of normal human astrocytes in 3D culture, Figure S7:
Internalization of fluorescent dPGS-Cy5 in glioblastoma tumoroids.
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